

Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake

Anne-Kathrin Wermter^{aa} André Scherag^{b,ca} Katja Hölter^{aa} Kathrin Reichwald^{d,ea}
Peter Lichtner^f Wolfgang Siegfried^g John Blundell^h Clare Lawton^h Stephen Whybrowⁱ
James Stubbs^j Jonathan R. Arch^k Thomas Meitinger^{f,l} Matthias Platzer^e Anke Hinney^d
Johannes Hebebrand^d

^a Department of Child and Adolescent Psychiatry, University of Marburg,

^b Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen,

^c Institute of Medical Biometry and Epidemiology, Philipps-University of Marburg,

^d Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen,

^e Leibniz Institute for Age Research – Fritz Lipmann Institute (FLI), Jena,

^f Department of Human Genetics, Helmholtz Center Munich, Neuherberg,

^g Obesity Treatment Center Insula, Berchtesgaden, Germany

^h Institute of Psychological Sciences, University of Leeds,

ⁱ The Rowett Research Institute, Aberdeen,

^j Nutrition and Research Department, Slimming World, Alfreton, Derbyshire, UK

^k Clore Laboratory, University of Buckingham, UK

^l Department of Human Genetics, Technical University Munich, Germany

Key Words

Enterostatin · Body weight regulation · Association · Single nucleotide polymorphism · Mutation screen

Summary

Background: Several lines of evidence indicate an involvement of procolipase (CLPS) or its derivative enterostatin in dietary fat absorption, regulation of fat intake, and body weight in rodents. We explored the relationship between genetic variation in *CLPS*, early-onset obesity and fat intake in humans. **Methods:** We screened the *CLPS* in 93 extremely obese children and adolescents and 96 underweight young adults for sequence variations and genotyped single nucleotide polymorphisms (SNPs) in extremely obese children and adolescents, healthy normal- and underweight young adults and obesity trios. Case-control and family-based association analyses were performed. **Results:** Five sequence variations were identified: two non-synonymous SNPs: rs2766597 (Leu8Pro), rs41270082 (Arg109Cys); one SNP in the 5'UTR: rs3748050; one intronic SNP: rs3748051; and one infrequent novel non-synonymous variant: Arg55His. For rs2766597, rs3748050, and rs3748051 we obtained no evidence for an association with obesity in the case-control comparison. For rs41270082 there was a

trend for association which could not be substantiated in the family-based association analysis. Additionally, we found no association in subgroup analyses pertaining to the extremely obese children and adolescents in the lowest and highest quartile of the percentage of energy consumed as fat. **Conclusions:** We found no evidence for an association of *CLPS* SNPs rs2766597, rs41270082, rs3748050, and rs3748051 with obesity or percentage of dietary fat intake.

Introduction

The colipase preproprotein (CLPS) is present in exocrine pancreatic cells and is secreted into the pancreatic juice [1]. *CLPS* expression is increased during feeding on fat and might provide a feedback signal for the inhibition of high levels of fat feeding [2]. After activation by trypsin, procolipase is split into the N-terminal pentapeptide enterostatin and the 90 amino acid (aa) mature protein colipase [3]. The role of colipase is to restore the activity of pancreatic lipase in the presence of inhibitory substances like bile acids [4]. Hence, it may be essential for the efficient digestion of dietary fat. *Clps*^{-/-} mice show decreased postnatal survival and weight gain, steatorrhea on a high-fat diet, and reduced body weight com-

Table 1. Anthropometric data of extremely obese children and adolescents (cases), underweight young adults (controls) and obese trio families (obese children and adolescents and both biological parents)^a

Study group	Number	Female/male	BMI, kg/m ²	Age, years	Fat intake ^b , %
Case sample of obese children and adolescents	304	163/141	33.47 ± 6.27 (28.74;32.46;36.73)	13.98 ± 2.35 (12.53;14.02; 15.57)	ND
Obese children and adolescents, LF consumer cases	45	29/16	31.07 ± 1.99 (27.10;29.66;33.49)	13.57 ± 2.18 12.41; 13.53 14.91)	32.11 ± 4.15 (30.00;33.00;35.00)
Obese children and adolescents, HF consumer cases	48	20/28	32.15 ± 5.44 (27.30;30.69;35.90)	13.50 ± 1.98 12.48; 13.28;15.00)	45.46 ± 2.24 (43.00;45.50;47.00)
Control sample of healthy underweight individuals	325	157/168	19.36 ± 1.99 (17.72;18.95;20.79)	25.16 ± 3.48 (22.63;24.73;26.80)	ND
Obese offspring (children and adolescents)	365	156/209	31.81 ± 6.04 (27.59;31.00;34.85)	13.75 ± 3.08 (12.14;13.84;15.58)	ND
Parents	730	365/365	29.96 ± 6.22 (25.59;29.10;33.17)	42.68 ± 6.47 (38.33;42.47;46.32)	ND

^a Values are given as absolute frequencies, mean ± SD and 1st, 2nd and 3rd quartile (in parentheses). Note that not all individuals were genotyped for all markers.

^b As measured by the Leeds Food Frequency Questionnaire. HF = High fat; LF = low fat; ND = not determined.

pared to their *Clps*^{-/-} and wild-type littermates [5]. This indicates that colipase, or its precursor procolipase, has additional functions in dietary fat digestion and body weight regulation in the period after birth when pancreatic lipase is not expressed. Studies involving the administration of enterostatin, either centrally or peripherally, demonstrated a dose-dependent and specific inhibition of fat intake in rats given a choice between fat, carbohydrate and protein [6], or an inhibition of high-fat intake as opposed to low-fat intake in a two-choice situation [7]. The inhibition of fat intake by enterostatin has been characterized as an induction of early satiety [8]. Enterostatin acts through an interaction with a postulated μ -opioid pathway that affects reward perception and the production of ATP through an interaction with the β -subunit of F1F0 ATPase [9, 10]. In addition, there is evidence that enterostatin inhibits dietary fat intake through a melanocortin signaling pathway [11]. The effect of substances that stimulate fat intake, such as galanin [8], opioids [12–14] and glucocorticoid hormones [15], could be reduced by enterostatin treatment. In long-term studies enterostatin was shown to decrease food intake and reduce body fat and body weight in rodents on a high-fat diet [16, 17]. Reduction of insulin and stimulation of corticosterone secretion [17, 18], sympathetic stimulation of brown adipose tissue [19], and an increased thermogenesis [20] have been suggested to contribute to these effects. In humans, it was suggested that enterostatin secretion might be reduced in obesity, in both fasting and postingestive states [2, 21]. However, in clinical trials intravenous [22] and oral [23] administration of enterostatin did not reduce food intake in human subjects.

The human procolipase gene (*CLPS*) is localized on chromosome 6p21.31 and encodes a 112 aa preprotein. Given the

presumed importance of CLPS for the regulation of fat intake and body weight regulation, we investigated if genetic variation in the *CLPS* is associated with early-onset obesity and fat intake in German samples comprising extremely obese children and adolescents and lean controls or nuclear families with extremely obese offspring.

Patients and Methods

Study Subjects

The ascertainment strategy was previously described in detail [24]. All extremely obese children and adolescents had an age- and gender-specific BMI percentile of 90 or higher as discussed previously [25] (98% had a percentile > 99). However, only parts of the total sample (table 1) were genotyped for each marker (table 2). The total case sample comprised 304 extremely obese German children and adolescents who were recruited in hospitals specialized for the treatment of young in-patients with extreme obesity. 93 extremely obese children and adolescents, a subgroup of cases, were classified into 48 habitual high-fat (HF; 43–51% energy from fat) and 45 low-fat (LF; 21–36% energy from fat) consumers [27]. The percentage of energy consumed as fat was assessed using the 'Leeds Food Frequency Questionnaire' (Leeds FFQ) [26], which was adapted for German nutritional habits. Consistency of the adapted FFQ was evaluated using a short FFQ validated in Germany [28]. The control sample comprised 325 healthy normal weight and underweight students; about 70% were lean (<15th percentile). They were recruited at the University of Marburg and reimbursed for their voluntary participation. The genotyped trio family sample included 365 extremely obese children and adolescents and both biological parents. All three samples were independent (table 1). Written informed consent was given by all participants and, in the case of minors, their parents. This study was approved by the Ethics Committee of the University of Marburg and carried out in accordance with the Declaration of Helsinki.

Table 2. Genotype distributions and association analyses for four *CLPS* SNPs on chromosome 6 in obese children and adolescents (cases) compared with underweight and normal weight young adults (controls). In addition a subgroup of the obese children and adolescents was derived from the quartiles of percentage of energy consumed fat (LF vs. HF consumers) and compared with each other or with the controls^a

Marker genotypes	Physical position (bp) dbSNP127	Cases		Controls		OR estimate p value	LF consumer cases		HF consumer cases		OR estimate p value		
		n	%	n	%		%	n	%	n	%	LF vs. HF	LF vs. controls
rs2766597	35873021												
CC		0	0.0	0	0.0	0.35	0	0.0	0	0.0	ND	ND	0.70
TC		2	2.1	19	5.9	(0.04; 1.48)	0	0.0	2	4.2			(0.08; 3.07)
TT		93	97.9	306	94.1	0.22	45	100.0	46	95.8	0.53	0.16	0.95
rs3748050	35873046												
GG		1	1.2	8	3.9	0.82	1	2.2	0	0.0	0.67	0.71	1.07
AG		35	42.2	91	44.4	(0.47; 1.41)	17	37.8	24	50.0	(0.27; 1.64)	(0.37; 1.38)	(0.54; 2.11)
AA		47	56.6	106	51.7	0.53	27	60.0	24	50.0	0.45	0.40	0.96
rs3748051	35872921												
GG		1	1.2	8	3.9	0.83	1	2.6	0	0.0	0.65	0.64	0.98
AG		36	43.4	93	45.4	(0.48; 1.43)	14	35.9	21	48.8	(0.25; 1.72)	(0.29; 1.37)	(0.48; 2.00)
AA		46	55.4	104	50.7	0.55	24	61.5	22	51.2	0.47	0.29	1.00
rs41270082	35870915												
TT		0	0.0	0	0.0	3.45	0	0.0	0	0.0	1.07	5.38	5.02
CT		12	4.4	3	1.3	(0.91; 19.25)	3	6.7	3	6.3	(0.14; 8.44)	(0.69; 41.18)	(0.65; 38.4)
CC		262	95.6	226	98.7	0.07	42	93.3	45	93.7	1.00	0.12	0.13

ND = Not determined.

^aOdds ratios (OR) estimates with 95% confidence intervals in parenthesis and p values were calculated under a dominant genetic model with the minor allele as risk allele.

Molecular Genetic Methods

We designed three primer pairs to amplify the entire coding region and splice sites of *CLPS*. Primers were derived from the genomic sequence (GenBank accession number: NT_007592; www.ncbi.nlm.nih.gov) as follows: *CLPS E1-F*: 5'-GGT CAG GGC CCC TTT TAT AG-3' and *CLPS E1-R*: 5'-TCA GAG GTC AAG GTC CAA GC-3'; 236 bp *CLPS E1* amplicon. *CLPS E2-F*: 5'-TGG GTA CAG GTC TGA ATG GA-3' and *CLPS E2-R*: 5'-GTG TTC AGG GCC CTA CTC C-3'; 250 bp *CLPS E2* amplicon. *CLPS E3-F*: 5'-AGG GGA CAA GTG ATG TCC AA-3' and *CLPS E3-R*: 5'-GCC TAC AGC ATT CTG GGC TA-3'; 239 bp *CLPS E3* amplicon. Polymerase chain reaction (PCR) was performed according to standard protocols. For the mutation screen, single strand conformation polymorphism analysis (SSCP) was performed as described previously [29]. All amplicons with SSCP patterns deviant from the wild-type pattern were sequenced as described previously [29]. To genotype Arg55His and rs41270082, a PCR with subsequent diagnostic restriction fragment length polymorphism analyses (RFLP) was performed. To genotype Arg55His, *CLPS E2* amplicon was digested by *Fau I* (NEB; G-allele: 150 bp and 100 bp, A-allele 250 bp). To genotype rs41270082, *CLPS E3* amplicon was digested by *Fok I* (NEB; C-allele: 239 bp, T-allele 183 bp and 56 bp). To genotype rs3748050 and rs3748051 we performed a tetra-primer ARMS-PCR [30] with the following primers:

– rs3748050 (*51-i-F*: 5'-CAC ACC AGC TGT CCC ACG CA-3', *51-i-R*: 5'-CAG GAG GAT CAG GAT CTT CTC CAT TGC-3', *51-o-F*: 5'-CCA CAG CAG ATT GGC CAC AGC T-3' and *51-o-R*: 5'-CCT GCC AGT CCA GGT GGA GAC A-3'). Sizes of the PCR products were 328 bp (outer primer pair), 204 bp (A-allele), and 171 bp (G-allele).

– rs3748051 (*51-i-F*: 5'-AAG CGC CTC CTG AGT CCA CA-3', *51-i-R*: 5'-GGT CCA AGC TTA GGA AGT CTT CAG CC-3', *51-o-F*: 5'-ACC ACA GCT GGC TCT GTC TCC C-3' and *51-o-R*: 5'-CCA GGT TGA GCT GCT GCT CTG A-3'). Sizes of the PCR products were 371 bp (outer primer pair), 198 bp (A-allele) and 219 bp (G-allele).

All PCR products were visualized on ethidium bromide-stained 2.5% agarose gels. Allele sizes were determined with a molecular weight standard (123 bp ladder, Gibco BRL, Karlsruhe, Germany). Trio analyses for rs41270082 were performed by high-throughput genotyping via matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF-MS), employing the homogeneous mass extension protocol provided by the manufacturer (Sequenom, San Diego, CA, US). Assays for the SNP were designed by the SpectroDesigner software (Sequenom). Note that different numbers of individuals were genotyped for each marker such that the numbers in table 1 and table 2 do not correspond, i.e. table 1 indicates the maximum number of individuals that could have been genotyped.

Statistical Analysis

Differences in genotype frequencies for a dominant genetic model between samples of unrelated subjects were investigated using Fisher's exact test. This genetic model was chosen because most SNPs had rather low minor allele frequencies, leading to a low number of observations per cell in the 2x3 frequency table. The exact version, i.e. the binomial test of the classical test [31] for transmission disequilibrium, was used for the trio analysis. All genotype distributions in controls and parents were tested for deviations from Hardy-Weinberg equilibrium (HWE)

using PEDSTATS 0.6.4 [32], and no evidence for such deviations were detected (all $p \geq 0.01$). As there was no evidence for a significant association, no correction for multiple testing was performed. All reported p values were nominal, two-sided, and exact. In addition, estimated odds ratios and 95% confidence intervals are provided under the dominant genetic model. For that same genetic model the power of the analysis was assessed with the software QUANTO Version 1.2.3 (<http://hydra.usc.edu/gxe>) for rs3748050 (HapMap-CEU minor allele frequency $\approx 29\%$). Based on this information 200 case-control pairs were estimated to yield a power $>80\%$ to detect a genetic odds ratio of 1.8 ($\alpha = 0.05$; two-sided). For the 365 trio families the power estimate was $>80\%$ to detect a genotype relative risk of 1.5 ($\alpha = 0.05$; two-sided). Thus, the association studies were only well powered to detect common disease-predisposing variants with strong genetic effects.

Results

The initial mutation screen of the coding sequence of *CLPS* in 93 extremely obese children and adolescents (a subgroup of the case sample) and 96 healthy lean young adults (a subgroup of the control sample) revealed two previously described missense SNPs (rs2766597 (Leu8Pro) and rs41270082 (Arg109Cys)) and two non-coding SNPs (rs3748050 in the 5'UTR and rs3748051 in intron 1). In addition, a novel non-synonymous, non-conservative variant (g.1515G>A: Arg55His) was found in one control proband in the heterozygous state. Due to its very low estimated minor allele frequency (MAF = 0.27% in our sample) and the low statistical power resulting, this variant was not evaluated further in the case-control association analyses. rs41270082 resulted in an Arg to Cys substitution at position 109 of *CLPS*. The case-control analysis revealed some evidence for a difference in T-allele frequencies between cases and controls ($p = 0.07$). In an attempt to substantiate this finding, we genotyped rs41270082 in the 365 obesity trio families. Only 3 transmissions versus 7 non-transmissions of the T-allele to the obese offspring could be detected by the transmission disequilibrium test (TDT) ($p = 0.34$). Hence, the initial result was not substantiated; descriptively the potential 'risk allele' was transmitted less frequently to the obese offspring. rs2766597 predicted a non-conservative aa exchange replacing Leu at position 8 of *CLPS* with Pro (Leu8Pro). Association analyses for rs2766597 and the other two detected SNPs (rs3748050 and rs3748051) revealed no differences in genotype distributions between extremely obese cases and controls (all $p \geq 0.2$).

Finally, we explored in 93 extremely obese individuals whether any of the genotyped SNPs might be more strongly associated with the dichotomized endophenotype 'percent of energy consumed as fat'. None of these additional comparisons revealed any evidence for differences in genotype frequencies between extremely obese patients of the low and high quartile of the percentage of energy consumed as fat (all $p \geq 0.4$) or for the comparisons to the lean controls (all $p \geq 0.1$).

Discussion

To determine the influence of genetic variants within *CLPS* on early-onset obesity in humans, we systematically screened the coding sequence of *CLPS* for sequence variations in a total of 189 German, extremely obese, normal or lean individuals. This sample size is sufficient to allow for the detection of common variants (e.g. assuming a minor allele frequency of 0.05, the total sample size produced a 95% confidence interval ± 0.03). Two previously described non-synonymous SNPs (rs2766597 and rs41270082) and two non-coding SNPs (rs3748050 in the 5'UTR and rs3748051 in intron 1) were identified along with one novel infrequent missense variant (Arg55His). In our association studies, we initially compared genotype frequencies of these four SNPs in *CLPS* between extremely obese children and adolescents and lean controls. While no evidence for an association for rs3748050, rs2766597, and rs3748051 was obtained, there was some evidence for an association between the T-allele of rs41270082 and obesity. This SNP, in codon 109 of *CLPS*, results in an Arg to Cys substitution. Since *CLPS* contains 10 Cys residues, which form 5 disulfide bridges, an additional Cys residue at position 109 may alter the bridge formation and therefore the stability, conformation and/or function of the protein. Because of these potential functional consequences, we performed subsequent TDTs in 365 obesity trios. Tests revealed no evidence for transmission disequilibrium and therefore did not substantiate the initial finding. However, it is possible that this result might only be due to the insufficient power of the family-based approach. Finally, we also assessed whether one of the four variants might be associated with differences in dietary fat consumption of extremely obese individuals defined by upper and lower quartiles within the case sample. As with the main finding, we found no evidence for differences in genotype frequencies between habitual high-fat and low-fat consumers. The same was true for the comparisons with the control group.

Association of rs3748050 and rs3748051 with reduced insulin secretion in non-diabetic Caucasians was recently detected [33]. Furthermore, previous work suggested a contribution of rs41270082 in *CLPS* to increased susceptibility to type 2 diabetes mellitus in two German study populations [34]. Very recently, evidence for an association with type 2 diabetes was detected in the EPIC-Potsdam cohort by screening for sequence variants in 15 genes involved in fat assimilation [35]. In an in vitro study rs41270082 was found to decrease the function of colipase [36]. So far, in public association databases associations of *CLPS* variants with obesity traits have not been reported. Studies of the potential implication of *CLPS* sequence variants in obesity would benefit from further analyses of rs41270082 in larger samples of obese subjects.

In conclusion, this investigation did not detect any common variants in the coding region and 5'UTR of *CLPS* with a major impact for the development of early onset obesity or habitual fat intake. However, larger samples will be neces-

sary to assess moderate genetic effects and their relationship to obesity. Even though limited by the small sample size, the present study may thus contribute to meta-analytic approaches addressing the role of the investigated polymorphisms for the development of early-onset extreme obesity.

Acknowledgements

We thank all probands and their families for their participation. This work was supported by grants from the German Ministry of Education

and Research (Bundesministerium für Bildung und Forschung), National Genome Net NGFN2 and plus (01GS0482), DHGP2 grant 01KW0007, EU Framework V (QLK1-CT-2000-00515) and by the Deutsche Forschungsgemeinschaft (DFG; HE 1446/4-1). The Deutsche Forschungsgemeinschaft (DFG) supported the ascertainment of probands and families. The skilful technical assistance of Gerti Gerber and Uta Petz was highly appreciated.

Disclosure

The authors declared no conflict of interest.

References

- Erlanson-Albertsson C: Enterostatin: the pancreatic procolipase activation peptide – a signal for regulation of fat intake. *Nutr Rev* 1992;50:307–310.
- Mei J, Bowyer RC, Jehanli AM, Patel G, Erlanson-Albertsson C: Identification of enterostatin, the pancreatic procolipase activation peptide in the intestine of rat: effect of CCK-8 and high-fat feeding. *Pancreas* 1993;8:488–493.
- Erlanson-Albertsson C, Larsson A: The activation peptide of pancreatic procolipase decreases food intake in rats. *Regul Pept* 1988;22:325–331.
- van Tilbeurgh H, Bezzine S, Cambillau C, Verger R, Carriere F: Colipase: structure and interaction with pancreatic lipase. *Biochim Biophys Acta* 1999; 1441:173–184.
- D'Agostino D, Cordle RA, Kullman J, Erlanson-Albertsson C, Muglia LJ, Lowe ME: Decreased postnatal survival and altered body weight regulation in procolipase-deficient mice. *J Biol Chem* 2002;277:7170–7177.
- Okada S, York DA, Bray GA, Erlanson-Albertsson C: Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectively reduces fat intake. *Physiol Behav* 1991;49:1185–1189.
- Erlanson-Albertsson C, Mei J, Okada S, York D, Bray GA: Pancreatic procolipase propeptide, enterostatin, specifically inhibits fat intake. *Physiol Behav* 1991;49:1191–1194.
- Lin L, McClanahan S, York DA, Bray GA: The peptide enterostatin may produce early satiety. *Physiol Behav* 1993;53:789–794.
- Berger K, Winzell MS, Mei J, Erlanson-Albertsson C: Enterostatin and its target mechanisms during regulation of fat intake. *Physiol Behav* 2004;83:623–630.
- Park M, Lin L, Thomas S, Braymer HD, Smith PM, Harrison DH, et al: The F1-ATPase beta-subunit is the putative enterostatin receptor. *Peptides* 2004;25: 2127–2133.
- Lin L, Park M, York DA: Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system. *Peptides* 2007;28:643–649.
- Ookuma K, Barton C, York DA, Bray GA: Effect of enterostatin and kappa-opioids on macronutrient selection and consumption. *Peptides* 1997; 18:785–791.
- Lin L, Umahara M, York DA, Bray GA: Beta-casomorphins stimulate and enterostatin inhibits the intake of dietary fat in rats. *Peptides* 1998;19: 325–331.
- White CL, Bray GA, York DA: Intra-gastric beta-casomorphin(1-7) attenuates the suppression of fat intake by enterostatin. *Peptides* 2000;21:1377–1381.
- Mizuma H, Abadie J, Prasad C: Corticosterone facilitation of inhibition of fat intake by enterostatin (Val-Pro-Asp-Pro-Arg). *Peptides* 1994;15:447–452.
- Lin L, York DA: Chronic ingestion of dietary fat is a prerequisite for inhibition of feeding by enterostatin. *Am J Physiol* 1998;275:R619–R623.
- Okada S, Lin L, York DA, Bray GA: Chronic effects of intracerebral ventricular enterostatin in Osborne-Mendel rats fed a high-fat diet. *Physiol Behav* 1993;54:325–329.
- Mei J, Cheng Y, Erlanson-Albertsson C: Enterostatin – its ability to inhibit insulin secretion and to decrease high-fat food intake. *Int J Obes Relat Metab Disord* 1993;17:701–704.
- Nagase H, Bray GA, York DA: Effect of galanin and enterostatin on sympathetic nerve activity to interscapular brown adipose tissue. *Brain Res* 1996;709:44–50.
- Rippe C, Berger K, Boiers C, Ricquier D, Erlanson-Albertsson C: Effect of high-fat diet, surrounding temperature, and enterostatin on uncoupling protein gene expression. *Am J Physiol Endocrinol Metab* 2000;279:E293–E300.
- Prasad C, Imamura M, Debata C, Svec F, Sumar N, Hermon-Taylor J: Hyperenterostatinemia in premenopausal obese women. *J Clin Endocrinol Metab* 1999;84:937–941.
- Rossner S, Barkeling B, Erlanson-Albertsson C, Larsson P, Wahlin-Boll E: Intravenous enterostatin does not affect single meal food intake in man. *Appetite* 1995;24:37–42.
- Kovacs EM, Lejeune MP, Westerterp-Plantenga MS: The effects of enterostatin intake on food intake and energy expenditure. *Br J Nutr* 2003;90: 207–214.
- Hinney A, Lentes KU, Rosenkranz K, Barth N, Roth H, Ziegler A, et al: Beta 3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa. *Int J Obes Relat Metab Disord* 1997;21:224–230.
- Hebebrand J, Himmelmann GW, Hesecker H, Schafer H, Renschmidt H: Use of percentiles for the body mass index in anorexia nervosa: diagnostic, epidemiological, and therapeutic considerations. *Int J Eat Disord* 1996;19:359–369.
- Cooling J, Blundell J: Differences in energy expenditure and substrate oxidation between habitual high fat and low fat consumers (phenotypes). *Int J Obes Relat Metab Disord* 1998;22:612–618.
- Schauble N, Reichwald K, Grassl W, Bechstein H, Muller HC, Scherag A, et al: Human galanin (GAL) and galanin 1 receptor (GALR1) variations are not involved in fat intake and early onset obesity. *J Nutr* 2005;135:1387–1392.
- Rohrmann S, Klein G, Miller A: Validierung eines Kurzfragebogens zur Erfassung von Gesamtfett, gesättigten Fettsäuren, einfach und mehrfach ungesättigten Fettsäuren sowie Cholesterin. *Proc German Nutr Soc* 2001;3:P13.
- Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, et al: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. *J Clin Endocrinol Metab* 1999;84:1483–1486.
- Ye S, Dhillon S, Ke X, Collins AR, Day IN: An efficient procedure for genotyping single nucleotide polymorphisms. *Nucleic Acids Res* 2001;29:E88.
- Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* 1993;52:506–516.
- Wigginton JE, Cutler DJ, Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. *Am J Hum Genet* 2005;76:887–893.
- Weyrich P, Albet S, Lammers R, Machicao F, Fritsche A, Stefan N, Häring HU: Genetic Variability of Procolipase Associates with Altered Insulin Secretion in Non-diabetic Caucasians. *Exp Clin Endocrinol Diabetes* 2008; DOI: [10.1055/s-2008-1078733](https://doi.org/10.1055/s-2008-1078733).
- Lindner I, Helwig U, Rubin D, Li Y, Fisher E, Boeing H, et al: Putative association between a new polymorphism in exon 3 (Arg109Cys) of the pancreatic colipase gene and type 2 diabetes mellitus in two independent Caucasian study populations. *Mol Nutr Food Res* 2005;49:972–976.
- Fisher E, Nitz I, Lindner I, Rubin D, Boeing H, Mohlig M, et al: Candidate gene association study of type 2 diabetes in a nested case-control study of the EPIC-Potsdam cohort – role of fat assimilation. *Mol Nutr Food Res* 2007;51:185–191.
- D'Silva S, Xiao X, Lowe ME: A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides. *J Lipid Res* 2007;48:2478–2484.